Emmetrope
La Canada Flintridge
About Emmetrope
Emmetrope is developing next-generation accommodative lenses. The holy grail of accommodative lenses must deliver a lens that accommodates at least two diopters, has a stable effect, is placed in the capsular bag and is compatible with modern cataract technique. Emmetrope is well on its way to achieving this goal. They are a small angel-funded company, but they have taken their first lens, called Actalens™, through clinical testing. The results, presented at ESCRS and currently in press, show that their lens outperforms other lenses in terms of anterior movement with accommodation. This accommodative movement has recently been independently validated and shown to be stable out to 20 months post surgery. Emmetrope, despite its size, now has best in class movement and stability of effect. Their final push toward the ultimate accommodative lens is about to begin. Computer modeling with finite element analysis demonstrates that their ActaLens platform, in its two layer embodiment, will yield a shape-change lens that offers over three diopters of accommodation. They are seeking series A financing to model, produce and clinically test this next generation shape change lens as well as take their first generation lens through CE mark and launch. The two year goal is specific and would have tremendous financial return for their company. They want to employ their validated Actalens platform to produce a shape-change lens with unprecedented objective accommodation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Estimated revenue: $1K – $10K
- Last round: Grant (Jun 2015)
- Website: actalens.com
Industries & Categories
Health Care, Medical
Canonical: https://fsome.com/organization/emmetrope-2890565 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.